Summary
The mechanism for renal handling of carboplatin was studied in 17 ovarian cancer patients treated with a combination of carboplatin and cyclophosphamide. Carboplatin and [51Cr]-ethylenediaminetetraacetic acid (EDTA) renal clearances were measured simultaneously during short intervals of from 45 to 120 min. A total of 131 clearance intervals were analyzed during 35 chemotherapy courses. The carboplatin/[51Cr]-EDTA clearance ratio (R) served as an indicator of the net tubular reabsorption (R<1) or secretion (R>1). The R value was calculated for each sampling interval. No significant difference was found between interpatient and intertreatment variation. The intertreatment variation as tested against the variation in the short intervals by anF-test was highly significant. We calculated the average R value for each treatment and consequently based our results on a total of 35 observations. The mean R value was 0.77 (t-test for R=1;P<0.001). We conclude that the renal elimination of carboplatin takes place by glomerular filtration followed by tubular reabsorption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brøchner-Mortensen J (1972) A simple method for determination of glomerular filtration rate. Scand J Clin Invest 30: 271
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR (1985) Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12 [Suppl A]: 51
Calvert AH, Newell DR, Gumbrell LA, O-Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748
Duncan GF, Faulkner HC, Farmen RH, Pittman KA (1988) Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate. J Pharm Sci 77: 273
Reference deleted
Elferink F, Vijgh WJF van der, Klein I, Vermorken JB, Gall HE, Pinedo HM (1987) Pharmacokinetics of carboplatin after i. v. administration. Cancer Treat Rep 71: 1231
Freedman LS, Workman P (1988) When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? Cancer Chemother Pharmacol 22: 95
Gaver RC, Colombo N, Green MD, George AM, Deeb G, Morris AD, Canetta RM, Speyer JL, Farmen RH, Muggia FM (1988) The disposition of carboplatin in ovarian cancer patients. Cancer Chemother Pharmacol 22: 263
Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetics ofcis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693
Jacobs C, Kalman SM, Tretton M, Weiner MW (1980) Renal handling ofcis-diamminedichloroplatinum(II). Cancer Treat Rep 64: 1223
Reece PA, Bishop JF, Olver IN, Stafford I, Hillcoat BL, Morstyn G (1987) Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small-cell lung carcinoma. Cancer Chemother Pharmacol 19: 326
Siddik ZH, Newell DR, Boxall FE, Harrap KR (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36: 1925
Author information
Authors and Affiliations
Additional information
Supported by grants from the Lundbeck Foundation and the Danish Cancer Society
Rights and permissions
About this article
Cite this article
Sørensen, B.T., Strömgren, A., Jakobsen, P. et al. Renal handling of carboplatin. Cancer Chemother. Pharmacol. 30, 317–320 (1992). https://doi.org/10.1007/BF00686302
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686302